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Abstract. Urokinase-type plasminogen activator (uPA) and
its specific membrane receptor (uPAR) control extracellular
matrix proteolysis, cell migration, invasion and cell growth
in several cancers. The uPAR released from human cancers is
detected in blood as soluble uPAR (suPAR). No information is
available on the mechanism(s) of action of suPAR on prostate
cancer (PCa) cell growth and invasion. In order to clarify this
issue, we tested the effect of a treatment with the human
recombinant suPAR (comprising amino acids l-303) on the
proliferation, migration and invasion of DU145 cells, a PCa
cell line expressing a potent autocrine uPA-uPAR signalling
system. The results indicate that suPAR significantly inhibits
cell growth, promotes apoptosis and decreases both migration
and Matrigel™ invasion of DU145 cells. The mechanism of
action of suPAR seems to be linked to a decrease of ERK and
FAK activation. Cleavage of suPAR by chymotripsin reverses
these effects. When added to the uPA-negative LNCaP cells,
suPAR was ineffective; on the contrary, when LNCaP cells
were cultured on fibronectin-coated plates in order to stimulate
uPA expression, suPAR significantly decreased cell prolifer-
ation. In conclusion, our data suggest that suPAR can function
as a potent molecule scavenger for uPA in human PCa cells
characterized by high levels of uPA/uPAR as in DU145 cells,
while it is ineffective in uPA-deficient LNCaP cells. The
molecular mechanism(s) through which suPAR participates
in the control of PCa progression may bear relevance for the
long-term goal to identify new therapeutic targets aimed at
silencing tumours in vivo. 
Introduction
Advanced prostate cancer (PCa) morbidity and mortality are
strictly correlated with a higher proliferation rate and metastatic
progression (1). Little information is available on the molecular
mechanism(s) involved in the control of the metastatic
properties of PCa cells. 
The processes of tissue remodelling associated with cancer
invasion and metastasis are controlled by proteolytic enzymes,
which participate in the extensive disruption of cell/cell and
cell/extra-cellular matrix (ECM) contacts (2). The tumour cell-
associated urokinase-type plasminogen activator (PA) system,
consisting of the serine protease uPA, its substrate plasminogen,
the membrane-bound receptor uPAR, as well as the inhibitors
PAI-1/2, plays an important role in these pericellular processes
and it is implicated in PCa progression and invasion (3-5).
uPA is secreted as an inactive pro-enzyme, which localizes
on the cell surface by binding uPAR (6). The human receptor
uPAR consists of 3 homologous domains (D1, D2 and D3)
linked to the membrane by a glycosylphosphatidylinositol
(GPI) anchor at the C-terminus (7). Since the amino-terminal
domain (D1) is required for the binding to uPA, all three
domains are needed for high affinity binding (8,9).
The presence of the uPA/uPAR system provided by the
tumour cells may be sufficient to modulate directional
proteolysis through the activation of plasminogen, initiating a
proteinase cascade which culminates in metalloproteinase
activation and degradation of extracellular matrix proteins
(10-13). 
uPAR laterally associates with several trans-membrane
receptors, including integrins and the EGFR within the same
plasma membrane. By regulating the activity of integrins and
EGFR, uPAR also participates in the control of extracellular
signals controlling cell growth (14).
The uPA/uPAR complex is capable of activating a number
of pathways (15,16). In many cell types, when uPA binds
to uPAR, it activates signal transduction and protein tyrosine
kinases, including focal adhesion kinase (FAK) (17) and
extracellular signalling regulated kinase (ERK) (18,19).
Otherwise, vitronectin, as another ligand of uPAR, is able to
activate distinct cell-signalling pathways from that controlled
by uPA such as the small GTPase, Rac1, and thereby regulates
downstream factors involved in new actin polymerization
(20,21). 
Overexpression of components of the uPA-system in non-
metastatic cells enhances metastasis; inhibition of uPA and/or
of the uPA/uPAR interaction prevents or reduces metastasis
in animal models (22,23). Reduced metastasis of transgenic
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mammary cancer is reported in urokinase deficient mice (24).
Furthermore, antimetastatic drugs such as GnRH analogues
widely used for PCa treatment exhibit not only an anti-
proliferative effect, but also inhibitory effects on uPA secretion
(25). 
A soluble form of uPAR (suPAR) lacking the GPI-anchor
has also been found both in vivo and in vitro. Intact uPAR
is released from the plasma membrane by GPI-specific
phospholipase and proteases (26) and may also be generated
by alternative splicing of the uPAR mRNA (27). Cleaved
uPAR forms are present in several neoplastic cell lines and
tissues (28,29). In humans, suPAR, both intact and cleaved,
is found in blood, ascitic fluid, tissues and urine of many types
of cancer. Measurements of suPAR forms in squamous cell
lung cancer (30), colon cancer (31) and breast cancer (32) have
prognostic significance, since increased uPAR in blood is
correlated with poor prognosis (33,34). However, uPAR has
not been shown to be useful in PCa diagnostics (13,35),
even if measurements of individual cleaved forms of suPAR
contributed significantly to discrimination of men with PCa
from those with no evidence of malignancy (36,37). In animal
models, suPAR reduces in vivo the growth and metastasis of
MDA-MB 231 breast cancer cells and OV-MZ-6#8 ovarian
cancer cells (38,39). 
No information has been published so far regarding a
possible role of intact suPAR in the mechanisms controlling
PCa progression. 
To this purpose, we have studied the effect of suPAR on
cell growth, migration and invasion of PCa cells; the signalling
pathways affected by suPAR, especially in terms of ERK
and FAK activation, have been tested. Experiments have been
performed on PCa metastatic and androgen-independent
DU145, expressing high levels of uPA/uPAR. Moreover, we
have tested the effect of suPAR on cell growth of androgen-
dependent LNCaP; in these cells, uPA is not expressed at a
sufficient level to establish autocrine uPA/uPAR signalling.
Materials and methods
Reagents and antibodies. Recombinant human soluble uPAR
(suPAR), comprising the amino acids 1-303, was from R&D
Systems, Inc. (Minneapolis, MN). suPAR was dissolved in
sterile PBS containing 0.1% bovine serum albumin to prepare
a stock solution of 20 μg/ml.
Cleaved suPAR (CsuPAR) was prepared by treating suPAR
with 2.0 nM chymotrypsin for 7 h at 37˚C. The chymotrypsin
was inactivated with 1.0 mM PMSF, as described (40). Chymo-
trypsin and protease inhibitor mixture were from Sigma-
Aldrich (Milano, Italy). Antibodies to ERK1/2, FAK, uPA
and uPAR were from Santa Cruz (CA). Horseradish peroxidase
conjugated antibodies were from Santa Cruz (CA).
Cell culture. The PCa DU145 and LNCaP cells were obtained
from the American Type Culture Collection (Rockville, MD).
Cells were routinely grown in RPMI-1640 medium (Biochrom
KG, Berlin, Germany), supplemented with 5% foetal bovine
serum (FBS) that was obtained from Gibco BRL, Grand
Island, NY), glutamine (2 mM), penicillin (100 IU/ml), and
streptomycin (100 μg/ml) in a humidified atmosphere of 5%
CO2, 95% air at 37˚C.
In order to stimulate uPA production, the LNCaP cells
were plated in tissue culture wells pre-coated with fibronectin
(5 μg/ml, BD Biosciences).
Cell growth studies. DU145 cells, plated in 10-mm dishes in
serum-free medium, were treated for 48 h with suPAR (1.0-
10 nM). Cells were then harvested and counted by using a
haemocytometer. In another series of experiments, 1 μCi/ml
[3H]thymidine was added to DU145 and LNCaP cells. DU145
cells, cultured in serum-free medium, were incubated for
24 h with graded doses of suPAR (1.0-10 nM). Six hours
following [3H]thymidine addition, cells were washed in PBS
and radioactivity was counted in a ß-counter 1600CA TRI-
CARB (Perkin-Elmer). 
The results of three separate experiments are presented as
the mean ± SD. Each experimental group was composed of 8
replicates. Statistical analysis was performed by one-way
ANOVA followed by Tukey's multiple comparison tests.
p<0.05 was considered statistically significant.
FACScan analysis. For FACScan analysis, adherent DU145
cells, pre-treated with suPAR (10 nM) for 24 h in serum-free
medium, were harvested, pooled with the culture supernatant
containing the apoptotic cells already detached from the dish
and centrifuged. Cells (1x106) were washed in PBS, fixed in
70% ethanol, centrifuged, and re-suspended in DNA staining
solution (PBS containing 200 mg/ml RNase A, 20 mg/ml
propidium iodide plus 0.1% Triton X-100). Cells were then
stained by incubation at room temperature for 60 min. All
cells were then measured on a FACScan flow cytometer
(Becton Dickinson, UK) with an argon laser at 488 nm for
excitation and analyzed using Cell Quest software (Becton
Dickinson). All the flow cytometric measurements were made
using the same instrument settings, and at least 10,000 cells
were measured in each sample. A quantifiable peak detected
apoptotic cells in the sub-G1 phase corresponding to the red
fluorescence light emitted by sub-diploid nuclei of cells; the
results were expressed as the percentage of death by apoptosis
induced by suPAR treatment. The results of three separate
experiments are presented as the mean ± SD. Each experiment
was performed in triplicate. Statistical analysis was performed
by one-way ANOVA followed by Tukey's multiple comparison
tests. p<0.05 was considered statistically significant.
Migration and invasion assays. Briefly, cell migration assay
was performed using a 48-well Boyden chamber (Neuroprobe,
Inc) containing 8-μm polycarbonate filters (Nucleopore,
Concorezzo, Milan, Italy). Filters were coated on one side
with 50 μg/ml laminin, rinsed once with PBS, and then placed
in contact with the lower chamber containing RPMI-1640
medium. DU145 cells, pre-treated for 48 h with suPAR (1.0-
10 nM), were collected and then added in aliquots (75,000
cells/50 μl) to the top of each chamber and allowed to migrate
through coated filters for 4 h. At the end of the incubation,
the migrated cells attached to the lower membrane surfaces
were fixed, stained with Diffquik (Biomap, Italy) and counted
at a x40 magnification by standard optical microscopy.
Invasion assay was performed in invasion chambers
(Becton Dickinson, Bedford, MA) containing a membrane
coated with Matrigel™. The digestion of Matrigel allowed
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the migration of cancer cells. Briefly, DU145 cells, pre-treated
with suPAR (1.0-10 nM) for 48 h, were collected and 500 μl of
cell suspension (75,000 cells) was added to trans-well inserts
with an 8-μm pore size coated with Matrigel. In the lower
compartment of the invasion chamber 5% FBS-containing
medium was added as a chemo-attractant. After a 22-h incub-
ation period at 37˚C, cells that passed through the Matrigel-
coated filter into the bottom wells were fixed, stained with
Diffquik (Biomap, Italy) and counted at a x40 magnification
by standard optical microscopy. 
The results of three separate experiments of migration
and invasion are presented as the mean ± SD. Each experi-
mental group consisted of 12 samples. Statistical analysis was
performed by one-way ANOVA followed by Tukey's multiple
comparison tests. p<0.05 was considered statistically significant.
The results are expressed as a percentage of migrated
cells vs control cells.
Immunoblot analyses. DU145 cells plated in 10-mm dishes in
serum-free medium were treated with human recombinant
suPAR (10 nM) or CsuPAR (10 nM), as indicated. DU145
cells were harvested in RIPA buffer containing AEBSF (0.4 μg/
μl), leupeptin (1 μg/μl) and pepstatin A (1 μg/μl), centrifuged,
and washed in PBS. Protein concentration was determined
using the Bradford assay. Equal amounts of protein (50 μg)
were resolved by 10% SDS-polyacrylamide gel electrophoresis
(SDS-PAGE), for 1.5 h at 110 V. Proteins were blotted using
transfer apparatus (BIO-RAD Trans Blot semi-dry). The
membrane was washed with 10 mM Tris-HCl, 150 mM
NaCl, 0.1% Tween-20 (TBST) for 30 min, immersed in a
blocking solution with TBST and 5% (w/v) dry skimmed
milk, and then incubated with a diluted solution of the primary
antibody at 4˚C over night.
LNCaP cells were plated in 24-well plates pre-coated or
not with fibronectin (5 μg/ml) for 48 h. Cultures were then
washed with serum-free medium and incubated for 24 h with
suPAR (10 nM). The cell supernatants, after gel electrophoresis
(SDS-PAGE), were subjected to immunoblot analysis to detect
uPA.
For ERK1/2, FAK and uPA analyses, we used 1:100 mouse
monoclonal antibodies against P-ERK1/2 (E-4, Santa Cruz),
1:1000 rabbit polyclonal antibody against ERK1/2 (K-23, Santa
Cruz), 1:100 rabbit polyclonal antibodies against P-FAK (Ser
722, Santa Cruz), 1:100 rabbit polyclonal antibodies against
FAK (A-17, Santa Cruz) and 1:100 goat polyclonal antibody
against uPA (C-20, Santa Cruz). 
After incubation, the membranes were washed and
incubated for 1 h with a secondary antibody conjugated with
peroxidase. (1:5000/1:10,000). Immunoreactive bands were
visualized using the enhanced chemiluminescence detection
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Figure 1. suPAR regulation of cell growth. DU145 cells, cultured in serum-free medium, were treated with suPAR (1.0-10 nM) for 48 h. At the end of the
treatments, cells were harvested and counted using a haemocytometer (A). [3H]thymidine incorporation on DU145 cells cultured in serum-free medium and
incubated for 24 h with graded doses of suPAR (1.0-10 nM). Cell number is expressed as a percentage of [3H]thymidine incorporation (B). The results of
three separate experiments are presented as the mean ± SD. Each experimental group was composed of 8 replicates. Cell cycle analysis of DU145 cells treated
with suPAR (C and D). The adherent DU145 cells were treated for 24 h with suPAR (10 nM) in serum-free medium. All cells were then measured on a
FACScan flow cytometer with an argon laser at 488 nm for excitation and analyzed using Cell Quest software. The results were expressed as the percentage
of cell death by apoptosis induced by suPAR treatment. Each experiment was performed in triplicate. Statistical analysis was performed by one-way ANOVA
followed by Tukey's multiple comparison tests. *p<0.05 vs controls was considered statistically significant.
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kit reagents (ECL Plus Western blotting detection system,
Amersham Biosciences, UK).
Results
suPAR regulation of cell growth. We undertook experiments
to examine the potential role of suPAR in regulating cell
growth in PCa DU145 cells. First of all, DU145 cells, cultured
for 48 h with suPAR (1.0-10 nM), were harvested and counted
using a haemocytometer. As shown in Fig. 1A, suPAR, at the
dose of 10 nM, inhibited the proliferation of DU145 cells.
Moreover, a 24-h treatment with 10 nM suPAR significantly
decreased [3H]thymidine incorporation of DU145 cells with
respect to untreated cells (Fig. 1B). FACScan analysis of
DU145 cells treated for 24 h with 10 nM suPAR indicated a
slight accumulation of cells in the G2/M cell cycle phase
(18.94±1.28%) with respect to untreated cells (13.59±1.67%)
(Fig. 1C) and a decrease in cells in the G0/G1 phase (suPAR
treated, 66.19±2.32%; controls, 71.33±2.93%); the S phase
population was essentially unchanged (suPAR-treated,
14.87±1.44%; controls, 15.08±1.85%). Moreover, apoptotic
cells in the sub-G1 phase were detected in DU145 cells treated
with suPAR (Fig. 1D). The results, expressed as the percentage
of death by apoptosis induced by suPAR treatment, show that
suPAR increased the number of apoptotic cells from 2 to 18%.
Effects of suPAR on cell migration and Matrigel™ invasion.
To test the effects of suPAR on DU145 cell migration and
invasion, we used haptotaxis assay and Matrigel invasion
chamber analysis. Fig. 2A shows that DU145 cells responded
to suPAR, decreasing the capacity to migrate in response to
laminin used as a haptotactic stimulus. In particular, exposure
to 10 nM suPAR reduced the migratory activity of DU145 of
41%.
The effect of suPAR was then evaluated on the ability of
DU145 to invade a tridimensional matrix of Matrigel. Fig. 2B
indicates that 10 nM suPAR exposure significantly inhibited
the invasiveness of DU145 cells (47% decrease) through the
Matrigel barrier. 
The effect of suPAR on ERK and FAK activation. To clarify
whether suPAR might modify ERK and FAK activation in PCa
cells, we performed immunoblotting on extracts of DU145
cells exposed for 2, 5 and 20 min to suPAR (10 nM). Fig. 3
demonstrates that, in our experimental conditions, both ERK
and FAK were activated in untreated DU145 cells. Moreover,
suPAR actually decreased ERK phosphorylation; this effect
was clearly evident after 5 min of treatment (Fig. 3A). At the
same time of observation, soluble uPAR (1.0-10 nM) was able
to decrease, in a dose-dependent manner, ERK phosphorylation;
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Figure 2. Effects of suPAR on cell migration and Matrigel invasion. DU145
cells were treated with suPAR (1.0-10 nM) in serum-free medium for 48 h;
cells were then detached, and transferred to a Boyden's chamber and Matrigel
invasion chamber. The results of three separate experiments are presented as
the mean ± SD. Each experimental group consisted of 12 samples. Statistical
analysis was performed by one-way ANOVA followed by Tukey's multiple
comparison tests. *p<0.05 vs controls was considered statistically significant.
The results are expressed as a percentage of migrated cells vs control cells.
Figure 3. Effects of suPAR on ERK activation. DU145 cells cultured in
serum-free medium were treated with suPAR (10 nM) for the indicated
times (A). DU145 cells were treated with graded doses of suPAR (0.1-10 nM)
for 5 min (B). The cell extracts were subjected to immunoblot analysis to
detect phosphorylated and total ERK1/2. Immunoreactive bands were detected
at 41-44 kDa. Blots are representative of 3 different experiments.
Figure 4. Effects of suPAR on FAK activation. DU145 cells cultured in
serum-free medium were treated with suPAR (10 nM) for the indicated
times. The cell extracts were subjected to immunoblot analysis to detect
phosphorylated and total FAK. An immunoreactive band was detected at
125 kDa. The same blots were successively incubated with an anti-actin
antibody to normalize FAK levels. Blots are representative of 3 different
experiments.
Figure 5. Effect of cleaved suPAR (CsuPAR) on ERK and FAK activation.
CsuPAR was prepared by treating suPAR with chymotrypsin (37˚C for 7 h).
DU145 cells, cultured in serum-free medium, were treated with either suPAR
(10 nM), or CsuPAR (10 nM) for 5 min. The cell extracts were subjected to
immunoblot analysis to detect ERK1/2 (A) and FAK (B) phosphorylation.
Blots are representative of 3 different experiments.
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the inhibition of ERK activation was consistently observed
with 10 nM suPAR (Fig. 3B). Then, we studied the effect of
treatment for 2, 5, and 20 min with suPAR (10 nM) on FAK
phosphorylation in DU145 cells (Fig. 4). Immunoblot analysis
of DU145 extracts also evidenced that suPAR produced a
decrease of FAK phosphorylation after 2 min of treatment,
and the effect was maintained for up to 20 min.
The cleavage of the protease sensitive region of uPAR
between D1 and D2 produces a short fragment (D2D3), which
no longer binds uPA (41). DU145 cells exposed for 5 min
to suPAR cleaved by chymotrypsin (CsuPAR) did not show
the decrease of ERK and FAK phosphorylation previously
described after suPAR treatment (Fig. 5A and B). 
suPAR regulation of [3H]thymidine incorporation in LNCaP
cells. To verify that the mechanism of action of suPAR is linked
to its capability to bind uPA, we performed experiments using
LNCaP cells that do not express uPA at a sufficient level to
establish autocrine uPA/uPAR signalling (42). However, when
seeded on fibronectin-coated plates, LNCaP cells secrete
detectable levels of uPA (43). In our experimental conditions,
LNCaP seeded on fibronectin (5 μg/ml) secreted in the cell
culture media higher amounts of uPA with respect to cells
plated in standard conditions (Fig. 6A). Then, we measured
[3H]thymidine incorporation on LNCaP cells plated (Fig. 6C)
or not (Fig. 6B) on fibronectin and treated for 24 h with graded
doses of suPAR (1.0-10 nM). LNCaP cells grown in standard
conditions did not evidence significant effects on [3H]thymidine
incorporation after suPAR exposure (Fig. 6B), whereas there
was a significant and dose-dependent decrease of the prolifer-
ation of LNCaP cells when plated on fibronectin-coated wells
(Fig. 6C).
Discussion
The present study was aimed at investigating whether soluble
uPAR is able to inhibit proliferation and/or invasion of PCa
cancer cells. In particular, we performed experiments on
the human prostate cancer cell line DU145, an androgen-
independent PCa cell line expressing an efficient uPA-uPAR
signalling system (42,44). We report, for the first time,
evidence demonstrating that soluble uPAR may antagonize
cell growth, promotes apoptosis and decreases both migration
and Matrigel invasion of PCa cells. 
The exogenous addition of recombinant suPAR signifi-
cantly decreases, in a dose-dependent manner, cell proliferation
and promotes apoptosis in DU145 cells. Since the activation
of uPAR by uPA triggers DU145 cell proliferation (reviewed
in ref. 14), one possible mechanism of action of suPAR
may be related to its capability to bind uPA, subtracting the
endogenous serino-protease from its membrane receptor on
tumour cells. In accordance with our data, other authors
(38,39,45) demonstrated a suppression of in vivo tumour
growth and metastasis of both MDA-MB-231 human breast
carcinoma and ovarian cancer OV-MZ-6#8 cells overexpressing
suPAR. 
The activation of the PA system is known to promote
different processes that involve cell migration, which are a
prerequisite for cell invasion and the establishment of meta-
stasis. Another biological effect of suPAR reported in the
present study on PCa cells was shown by in vitro migration
and invasion assays. We demonstrated that soluble uPAR is
able to influence the invasive activities of DU145 cells, since
it substantially decreases the capacity to migrate in response
to a haptotactic stimulus and the ability of the cells to invade
a tridimensional matrix of Matrigel.
It has been reported that the uPA/uPAR complex activation
is coupled to a number of intracellular pathways including
extracellular signalling regulated kinase (ERK). ERK activation
occurs in response to uPAR fractional occupancy, accounting
for the role of uPAR autocrine signalling in determining the
basal level of activated ERK in many cells (46,47). Moreover,
elevated focal adhesion kinase (FAK) expression has been
observed in different human cancer cell lines with increasing
tumorigenic potential (48-51) and FAK was found to be
phosphorylated upon uPA binding to uPAR in several cell
types (17). Our data sustain the observation that, in DU145 cells,
both ERK1/2 and FAK are activated in standard conditions;
moreover, the effects of suPAR on the proliferation and
migration of DU145 cells may be linked to a decrease of
ERK1/2 and FAK phosphorylation. 
The cleavage by chymotripsin prevents the inhibitory action
of suPAR on ERK1/2 and FAK activation in DU145 cells and
suggests different actions for suPAR and CsuPAR; furthermore,
it can be suggested that the breaking of suPAR by proteases
represents a mechanism by which cancer cells convert an
inhibitory molecule (suPAR) into an ineffective compound
(CsuPAR). To demonstrate that the action of suPAR in DU145
cells is linked to the capability of suPAR to scavenge uPA,
we performed experiments on LNCaP cells. In these PCa cells,
uPA is not expressed at a sufficient level to establish autocrine
uPA/uPAR signalling and, as a result, suPAR is unable to affect
LNCaP cell proliferation. By contrast, when we cultured
INTERNATIONAL JOURNAL OF ONCOLOGY  32:  185-191,  2008 189
Figure 6. Effect of suPAR on [3H]thymidine incorporation of LNCaP cells.
LNCaP cells were seeded in 24-well plates pre-coated (C) or not (B) with
fibronectin (5 μg/ml, FN). After 24 h, the cultures were washed with serum-
free medium and incubated for 48 h with suPAR (1.0-10 nM). The cell
media were subjected to immunoblot analysis to detect uPA at 33 kDa (A).
At the end of the treatments, LNCaP cells were subjected to [3H]thymidine
incorporation. Cell number is expressed as a percentage of [3H]thymidine
incorporation. The results of three separate experiments are presented as the
mean ± SD. Each experimental group was composed of 8 replicates. Statistical
analysis was performed by one-way ANOVA followed by Tukey's multiple
comparison tests. *p<0.05 vs controls was considered statistically significant.
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LNCaP cells on fibronectin-coated plates, an experimental
condition that stimulated uPA expression (43), suPAR signi-
ficantly decreased cell growth. Our data are in agreement
with the observations of Jo et al (19); these authors reported
that, in uPAR-deficient cells (uPAR-/- murine fibroblast or
human embryonic kidney 293 cells), both suPAR and CsuPAR
function as a partial signalling agonist that activates ERK.
On the contrary, in cells with a potent autocrine uPA-uPAR
signalling system (MDA-MB 231 breast cancer cells) suPAR
decreased ERK activation and inhibited proliferation, while
CsuPAR was ineffective. 
In accordance with the findings of other authors
(19,38,39,45,52), we propose that suPAR produces different
effects on PCa cell proliferation depending on the expression
of the endogenous uPA/uPAR system; moreover, we suggest
that intact suPAR may scavenge uPA and prevent uPA
binding to membrane-anchored uPAR, producing a decrease
in the level of activated ERK and FAK in PCa cells.
Prolonged uPAR suppression produces tumour cell
‘dormancy’, a dormant state during which tumour cells are
present but not seemingly biologically or clinically active
(reviewed in ref. 53). An increase of uncleaved suPAR able to
bind endogenous uPA may be important to control proliferation
and migration of cancer cells. 
Preliminary studies performed in our laboratory suggest
that drugs currently used for the therapeutic treatment of PCa,
such as GnRH analogues, seem to counteract the effect of
endogenous uPA through the increase of soluble uPAR in the
conditioned media of DU145 cells (unpublished data). Even
if further studies are needed to clarify the role of suPAR in
controlling PCa growth and invasion, the molecular mech-
anism through which suPAR participates in the biology of
advanced PCa cells evidenced in our studies by mechanisms
unrelated to plasminogen activation, is novel and entirely
untested and may bear relevance for the long-term goal to
identify new therapeutic targets aimed to trigger tumour
dormancy in vivo.
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